Serge Moresi will discuss concepts and techniques related to the analysis of potential coordinated effects in merger cases. For more information, click here.
What’s 340B? An economist’s view of the recent wave of 340B litigation
But this change has led to complex relationships among pharmaceutical manufacturers, hospitals, pharmacies, and third-party administrators, increasing...
